启明医疗-B宣布，其全球首创的全回收、自膨式干瓣经导管主动脉瓣置换（TAVR）系统Venus-PowerX，在中国的关键性临床试验患者入组工作已顺利完成。这一里程碑标志着该创新器械的临床验证进程取得了重大进展，为其未来在中国市场的商业化应用奠定了关键基础。作为世界首款具备完全回收与再定位功能的自膨式干瓣TAVR产品，Venus-PowerX旨在为主动脉瓣狭窄患者提供更安全、更精准的微创治疗选择。
启明医疗-B宣布，其全球首创的全回收、自膨式干瓣经导管主动脉瓣置换（TAVR）系统Venus-PowerX，在中国的关键性临床试验患者入组工作已顺利完成。这一里程碑标志着该创新器械的临床验证进程取得了重大进展，为其未来在中国市场的商业化应用奠定了关键基础。作为世界首款具备完全回收与再定位功能的自膨式干瓣TAVR产品，Venus-PowerX旨在为主动脉瓣狭窄患者提供更安全、更精准的微创治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.